VTCN1 Antibodies

Target Information

Negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. When expressed on the cell surface of tumor macrophages, plays an important role, together with regulatory T-cells (Treg), in the suppression of tumor-associated antigen-specific T-cell immunity. Involved in promoting epithelial cell transformation. Belongs to the immunoglobulin superfamily. BTN/MOG family. Overexpressed in breast, ovarian, endometrial, renal cell (RCC) and non-small-cell lung cancers (NSCLC). Expressed on activated T- and B-cells, monocytes and dendritic cells, but not expressed in most normal tissues (at protein level). Widely expressed, including in kidney, liver, lung, ovary, placenta, spleen and testis. 4 alternatively spliced human isoforms have been reported. Note: This description may include information from UniProtKB.

Alternate Names

B7 family member, H4; B7 homolog 4; B7 superfamily member 1; B7-H4; B7h.5; B7H4; B7S1; B7X; FLJ22418; Immune costimulatory protein B7-H4; PRO1291; Protein B7S1; RP11-229A19.4; T cell costimulatory molecule B7x; T-cell costimulatory molecule B7x; V-set domain containing T cell activation inhibitor 1; V-set domain-containing T-cell activation inhibitor 1; VCTN1; VTCN1